NYRADA INC.

3.85%

25.0¢

Market Cap $59.70M

Healthcare Biotechnology

Nyrada Inc is an Australia-based drug development company. The Company focuses on... Nyrada Inc is an Australia-based drug development company. The Company focuses on development of small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. Its drug development programs include a proprotein convertase subtilisin/kexin type nine (PCSK9) inhibitor for the treatment of high blood low-density lipoprotein (LDL)-cholesterol levels in patients poorly responsive to or unable to take statin drugs. It develops a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury. The Company also develops a drug to treat pain associated with peripheral nerve damage and autoimmune diseases such as psoriasis.More

Recce Pharmaceuticals (ASX:RCE) eyes US Defence grants with early data for R327 on burn wounds

Latest Threads

Tag

Subject

NYR

Ann: NYR Appoints Consultant Cardiologist for Phase IIa Trial

2 3

11:21

157

23K

11:21

Last post 3rdtimelucky

157

23K

NYR

CHART

2 3 4

31/08/25

202

42K

31/08/25

Last post Bendunstan

202

42K

NYR

Ann: Annual Report for year ended 30 June 2025

25/08/25

371

25/08/25

Last post R-7

371

NYR

Ann: Cleansing Statement

22/08/25

143

22/08/25

Last post

ASX News

143

NYR

Ann: Application for quotation of securities - NYR

22/08/25

132

22/08/25

Last post

ASX News

132

NYR

Ann: Notification regarding unquoted securities - NYR

22/08/25

127

22/08/25

Last post

ASX News

127

NYR

Ann: Full Year Results FY2025

22/08/25

571

22/08/25

Last post Bendunstan

571

NYR

Ann: Appendix 4G and Corporate Governance Statement

22/08/25

Last post

ASX News

See All Discussions

Timeline

Cleansing Statement
22 Aug 19:03	Share

Application for quotation of securities - NYR
22 Aug 18:56	Share

Notification regarding unquoted securities - NYR
22 Aug 18:52	Share

Full Year Results FY2025
22 Aug 09:41	Share

Annual Report for year ended 30 June 2025
22 Aug 09:40	Share

Appendix 4G and Corporate Governance Statement
22 Aug 09:38	Share

Preliminary Final Report
22 Aug 09:37	Share

Securities Trading Policy
22 Aug 09:33	Share

Notification regarding unquoted securities - NYR
20 Aug 16:38	Share

Response to ASX Cleansing Notice Timing Letter
14 Aug 09:44	Share

Cleansing Statement
13 Aug 18:23	Share

Application for quotation of securities - NYR
13 Aug 18:20	Share

NYR Appoints Consultant Cardiologist for Phase IIa Trial
13 Aug 09:15	Share

Cleansing Statement
11 Aug 09:53	Share

Application for quotation of securities - NYR
11 Aug 09:52	Share

Positive Final Review of Nyrada Phase I Clinical Trial
06 Aug 09:38	Share

BioShares Biotech Summit Presentation
06 Aug 08:24	Share

Change in substantial holding - M Azzi
05 Aug 10:25	Share

Cleansing Statement
04 Aug 11:15	Share

Application for quotation of securities - NYR
04 Aug 11:13	Share

Application for quotation of securities - NYR
04 Aug 11:10	Share

Proposed issue of securities - NYR
04 Aug 09:05	Share

Proposed issue of securities - NYR
04 Aug 09:05	Share

Nyrada Successfully Raises $8.25 Million via Placement
04 Aug 09:05	Share

Change in substantial holding - M Azzi
31 Jul 12:44	Share

Trading Halt
31 Jul 09:16	Share

Quarterly Activities Report and Appendix 4C
31 Jul 08:40	Share

Top 20 CDI Holder List
31 Jul 08:29	Share

NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
23 Jul 08:30	Share

Final Phase I Clinical Trial Patients Dosed and Discharged
21 Jul 08:26	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 25.0¢		Change -0.010(3.85%)		Mkt cap ! $59.70M

Open	High	Low	Value	Volume
26.0¢	26.0¢	23.5¢	$43.59K	176.7K

Buyers (Bids)

No.	Vol.	Price($)
1	21396	25.0¢

Sellers (Offers)

Price($)	Vol.	No.
25.5¢	24504	2

View Market Depth

No.	Vol.	Price($)
1	21396	0.250
3	91000	0.245
1	5000	0.240
1	3191	0.235
1	6521	0.230

Price($)	Vol.	No.
0.255	24504	2
0.260	140801	1
0.265	30000	1
0.270	58260	1
0.275	25000	1

Last trade - 16.10pm 01/09/2025 (20 minute delay)


Last 25.0¢		Change -0.010 ( 0.64 %)
Open	High	Low	Volume
25.3¢	25.3¢	23.5¢	148772
Last updated 15.53pm 01/09/2025 ?

NYR (ASX) Chart

NYRADA INC.

Latest Threads

Timeline

Featured News

Latest Articles

Nyrada pushes through to third cohort in Phase 1 trial for NYR-BI03

Nyrada Inc has been given the go-ahead to a third cohort in its Phase 1 clinical trial into its drug for neuroprotection and cardioprotection

Study finds Nyrada's lead drug can prevent secondary brain injury

Nyrada Inc has reported strong results from a collaborative study it has been engaged in regarding its lead candidate NYR-BI03

Nyrada doses first cohort in trial to assess neuroprotective, cardioprotective drug

Nyrada Inc has dosed the first cohort of patients in its Phase I first-in-human trial to assess the safety and tolerability of NYR-BI03

Buyers (Bids)

Sellers (Offers)

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

EV Resources executes strategic MOU with Wogen, XCLR to fund and advance Los Lirios antimony project

Top Stories

Featured News